OncoMatch

OncoMatch/Clinical Trials/NCT05101551

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Is NCT05101551 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Talazoparib and Topotecan for acute myeloid leukemia.

Phase 1RecruitingNorman J. LacayoNCT05101551Data as of May 2026

Treatment: Talazoparib · Topotecan · GemcitabineThis is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated dose of all 3 drugs when given in combination. A preliminary estimate of efficacy through a dose expansion phase is a secondary aim.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Prior therapy

Min 2 prior lines

Must have received: induction chemotherapy

refractory (persistent leukemia after at least 2 courses of induction chemotherapy) or relapsed

Lab requirements

Blood counts

WBC ≤ 50,000/uL (may be achieved using cytoreductive therapy such as hydroxyurea or low-dose cytarabine)

Kidney function

Estimated serum creatinine ≥ 60 mL/min/1.73m2

Liver function

Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) for age; AST/ALT ≤ 5 x ULN for age

Cardiac function

Left ventricular ejection fraction ≥ 40% or ECHO shortening fraction ≥ 25%

WBC ≤ 50,000/uL. Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) for age. AST/ALT ≤ 5 x ULN for age. Left ventricular ejection fraction ≥ 40% or ECHO shortening fraction ≥ 25%. Estimated serum creatinine ≥ 60 mL/min/1.73m2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Phoenix Children's Hospital · Phoenix, Arizona
  • Arkansas Children's Hospital · Little Rock, Arkansas
  • City of Hope · Duarte, California
  • Stanford University · Stanford, California
  • Cincinnati Children's Hospital · Cincinnati, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify